Financial & Business, OEM News

Danaher Closes $9.9B Acquisition of Masimo

Masimo will continue to operate under its own brand and will be a standalone operating company in Danaher’s Diagnostics segment.

Author Image

By: Sam Brusco

Associate Editor

Danaher announced that it has completed the acquisition of Masimo, a specialty diagnostics provider of pulse oximetry and patient monitoring solutions, mainly in acute care treatment settings.

The company believes Masimo’s trusted brand, advanced sensor tech, and artificial intelligence (AI)-enabled patient monitoring bring powerful new capabilities to its diagnostics portfolio. Masimo is now a wholly-owned subsidiary of Danaher and Masimo common stock has stopped trading on the Nasdaq market.

Masimo will continue to operate under its own brand and will be a standalone operating company in Danaher’s Diagnostics segment.

“Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo’s growth and global reach,” said Julie Sawyer Montgomery, executive VP of Diagnostics at Danaher. “We are excited to welcome the Masimo team to Danaher.”

The deal was valued at $180 per share in chase, representing a total value of about $9.9 billion.

Danaher said there will be no change to its previously communicated second quarter and full-year 2026 guidance range, excluding the expected contribution from Masimo. The company doesn’t expect a material contribution from Masimo in Q2 2026 and plans to update full-year 2026 guidance in connection with its Q2 earnings release to incorporate Masimo’s expected contribution.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters